Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Corrie, P., Qian, W., Gopinathan, A., Williams, M., Brais, R., Valle, J. W., Basu, B., Falk, S., Iwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bax, L., Bundi, P., Skells, R., Neesse, A., Tuveson, D., Jodrell, D. (September 2017) Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology, 28 (Supple). 73P. ISSN 0923-7534

URL: https://academic.oup.com/annonc/issue/28/suppl_5

Item Type:	Paper
Additional Information:	Meeting Abstract
Subjects:	diseases & disorders > cancer > drugs and therapies > chemotherapy Publication Type > Meeting Abstract diseases & disorders > cancer > cancer types > pancreatic cancer
CSHL Authors:	Tuveson, David A.
Communities:	CSHL labs > Tuveson lab
Depositing User:	Matt Covey
Date:	September 2017
Date Deposited:	25 Oct 2017 16:33
Last Modified:	29 Jan 2018 15:26
URI:	https://repository.cshl.edu/id/eprint/35580

Actions (login required)

Administrator's edit/view item